TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04057144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness exercises and audio recordings
Description: mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program
Description: Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity
Study: NCT04631510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg PO at 8 PM
Description: Administer gabapentin 300 mg PO at 8 PM for sleep
Study: NCT04027192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Matching Placebo tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Matching Placebo tablet, orally
Study: NCT02798666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise training
Description: Exercise training using sprint interval exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise training
Description: Exercise training using continuous exercise at constant heart rate
Study: NCT04076696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scatter corrected s-DCT
Description: All patients will have a breath held s-DCT scan in an anterior-posterior direction
Study: NCT04531176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Management Program (WMP)
Description: Weight Management Program (WMP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Management Program (WMP)
Description: Weight Management Program (WMP)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional care
Description: Traditional care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine / Topiramate Extended Release Oral Capsule
Description: Medication for chronic weight management (Rx)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion extended-release
Description: Medication for chronic weight management (Rx)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg
Description: Medication for chronic weight management (Rx)
Study: NCT04027192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Matching Placebo tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1 mg per day, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1 mg per day, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1 mg per day, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1 mg per day, orally
Study: NCT04531176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Medication for chronic weight management (Rx)
Study: NCT04271631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application-Based Diabetes Education
Description: Additional education was given using application, subjects were asked to open the application at least once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application-Based Diabetes Education
Description: Additional education was given using application, subjects were asked to open the application at least once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health coaching was given as face to face with a coach
Study: NCT05198011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D customized Titanium Mesh (Study)
Description: approach for planning and augmenting atrophic posterior mandibular ridge using a pre-customized TiMe on a 3D model. The 3D surgical model will be virtually created from a cone-beam computed tomography (CBCT) and printed using Fused deposition modeling (FDM) machine. The 3D model will be then used to contour the TiMe in accordance with the needed amount of augmentation then will be used to help pack and contour the graft material.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ridge augmentation (Control)
Description: the conventional technique of ridge augmentation using Titanium Mesh
Study: NCT03773978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02916212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized alarm profiles
Study: NCT02718898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02677493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG Quadrivalent Influenza Vaccine
Description: A single 0.5mL dose administrated as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Flu Vaccine Prefilled Syringe
Description: A single 0.5mL dose administrated as an intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-YANG Trivalent Influenza Vaccine
Description: A single 0.5mL dose administrated as an intramuscular injection.
Study: NCT00611936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 20mg maximum of d-amphetamine
Study: NCT01796145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibroscan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibroscan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibroscan
Study: NCT01650506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib dosing will start and remain at 150 mg daily.
Study: NCT02884869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubating Laryngeal Mask
Description: Direct laryngoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask
Description: Direct laryngoscopy
Study: NCT02706756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Hip joint and spine manual therapy techniques applied toward the impairments of the subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and advice
Description: All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and advice
Description: All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education and advice
Description: All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Supervised neglect
Description: Monitoring of group without formal intervention.
Study: NCT00641771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate sodium (+) cholecalciferol
Description: MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
Study: NCT03449017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cig use
Description: Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
Study: NCT00988494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-105 ophthalmic solution
Description: Topical ocular application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-105 ophthalmic solution
Description: Topical ocular application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ophthalmic solution
Description: Topical ocular application
Study: NCT02543684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ready to eat mixed meal 1
Description: wild greens pie providing 50g of carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ready to eat mixed meal 2
Description: chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ready to eat mixed meal 3
Description: vegetable moussaka providing 50g of carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose load
Description: glucose load providing 50g of carbohydrates
Study: NCT05207774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 8 weeks intranasal oxytocin 24 units per day. 8 units prior each meal. 4units/0.1 ml per puff

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 8 weeks intranasal placebo 0.6 ml per day. . 0.1 ml per puff
Study: NCT01345773

Intervention type: PROCEDURE
Intervention: Gastric surgery
Description: Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
Study: NCT04487366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reaching targeted area on the phantom model
Description: resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reaching targeted area on the phantom model
Description: resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reaching targeted area on the phantom model
Description: resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: reaching targeted area on the phantom model
Description: resident reach the targeted area on the phantom model using ultrasoun guidance and independently or with asistance inject the solution
Study: NCT01052493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP 1420
Description: Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP 1420
Description: Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP 1420
Description: Single dose of PP 1420, administered subcutaneously at either 2mg, 4mg or 8mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT03793244

Intervention type: DIETARY_SUPPLEMENT
Intervention: TARGET protocol EN 1.5 kcal/mL
Description: Enteral nutrition
Study: NCT04308122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Orthosis (CO)
Description: Immediately following surgery patients in the CO group will be fitted with a Philadelphia collar prior to being transferred to the recovery room. On the patient ward a physiotherapist will fit the patient with a Cervimax/Aspen/Miami J collar which will be worn at all times for 6 weeks according the standard of care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Orthosis
Description: The NO group will have no specific precautions applied to their neck range of motion.
Study: NCT01750203

Intervention type: OTHER
Intervention: Swabs
Description: There is no intervention only swabs are being used to collect wound fluid samples
Study: NCT04326517

Intervention type: PROCEDURE
Intervention: Nephrectomy
Description: Different therapeutic options are described in literature for emphysematous pyelonephritis. In our center, medical treatment (no invasive procedure), ureteral stent (endourologic procedure), percutaneous drainage (minimally invasive procedure), and nephrectomy are the therapeutic options for this disease.
Study: NCT03457493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714-PET/MRI
Description: DPA-714-PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714-PET/MRI
Description: DPA-714-PET/MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-year Follow-up DPA-714-PET/MRI
Description: PET/MRI scan with DPA-714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPA-714 Metabolite Analysis
Description: Participants will have an arterial line placed in their lower forearm immediately before DPA-714 PET/MRI. Serial blood samples will be pulled at specific time points during the dynamic PET/MRI.
Study: NCT02405689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Study: NCT02731469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131
Study: NCT02727062

Intervention type: DEVICE
Intervention: OM Pain App
Description: Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed. Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.

Intervention type: DEVICE
Intervention: Accelerometer
Description: Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period (weekly during radiation therapy and four weeks following radiation therapy).
Study: NCT03656510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 (high dose or low dose) orally twice daily for 7 days.
Study: NCT02731469

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mircera®
Study: NCT03656510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo (high volume or low volume) orally twice daily for 7 days.
Study: NCT02892786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating Tumor Cells
Description: Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years.
Study: NCT01092741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg P.O. twice daily (800 mg total daily dose)
Study: NCT02831387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-321 Ophthalmic Solution
Description: P-321 Ophthalmic Solution 0.017%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: P-321 Ophthalmic Solution placebo
Description: Placebo to match P-321 Ophthalmic Solution
Study: NCT01832285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: 100mg/day, PO(in the mouth) each day during 6 weeks
Study: NCT02731469

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aranesp®
Study: NCT03733717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous
Study: NCT02924428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Versa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Versa
Study: NCT01869582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetoscope, Fetal heart rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Resuscitator, Resuscitation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler, Fetal heart rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Resuscitator, Resuscitation
Study: NCT02724059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS with elastography followed by TBNA
Description: Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
Study: NCT03083353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: Isradipine will be administered 90 minutes prior to the initiation of cue exposure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue Exposure
Description: Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cue Exposure
Description: Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer virtual reality headset and handle cigarette packs to activate and extinguish craving.
Study: NCT02194673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans free palm margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans free palm margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans free palm margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interesterified Palm based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interesterified Palm based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interesterified Palm based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IE Soybean oil-based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IE Soybean oil-based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IE Soybean oil-based margarine
Description: A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.